Loading clinical trials...

BE WELL With Migraine: Brain Education and WELLness With Migraine | Clinical Trials | Clareo Health

RECRUITINGNA

BE WELL With Migraine: Brain Education and WELLness With Migraine

NCT05987592•Wake Forest University Health Sciences

Summary

The goal of this randomized clinical trial is to evaluate two different non-drug, virtual treatment options designed to improve the lives of patients with migraine. Both interventions involve 8 weekly sessions and an online platform with additional content and learning. Participants can stay on all their medications during this study. Information from this study may help determine how to better treat migraine.

Detailed Description

This study involves 8 weekly virtual sessions \& an online platform designed to improve the lives of patients with migraine. Participants from across the United States with migraine may be eligible to participate. This study does not require any in-person visits. All assessments and surveys will be completed virtually and/or online. Participants will independently complete an initial online screen. Participants will attend a scheduled phone or videoconferencing call with a study team member to complete the baseline assessment and learn how to use the online platform. Participants will keep an online daily headache log and complete several online surveys throughout the study.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of migraine with or without aura by with headache frequency of 4-20 days/month
•At least 1 year of migraine
•At least 18 years old
•Able to participate in 8 weekly online classes
•Willingness to complete baseline headache logs
•Headache-related disability (Headache Impact Test (HIT)-6) score \>50
•Fluent in English
•Completion of technology onboarding with the online platform
•Pregnant women who are less than or equal to 16 weeks gestation at enrollment are allowed to participate

Exclusion Criteria

•Major unstable medical/psychiatric condition that could be unsafe for participants or for the group environment.
•Medication overuse headache, with migraine treatment
•Pregnant women who are more than 16 weeks gestation at enrollment
•Unstable migraine treatment at enrollment: any preventive treatment (oral or injectable medication or neuromodulatory device) started within 12 weeks OR acute treatment within 4 weeks to ensure stability
•Unwillingness to maintain stable current medication dosages for study duration
•Failure to complete baseline headache logs
•Heavy alcohol and illicit drug use
•Participation in another intervention clinical trial or one that would interfere in this study
•Experience with stress reduction training (daily meditation practice, regular use of a mindfulness app, or prior experience with MBSR)
•Any, and all other diagnoses or conditions which, in the opinion of the site investigator, would prevent the patient from being a suitable candidate for the study or interfere with the medical care needs of the study participant: COVID-positive test within 30 days of enrollment

Locations (3)

Cambridge Health Alliance - Center for Mindfulness and Compassion

Cambridge, Massachusetts, United States

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Key Dates

Start Date

July 31, 2024

Primary Completion Date

December 30, 2026

Completion Date

June 30, 2027

Last Updated

May 29, 2025

Enrollment

286

ESTIMATED participants

Conditions

Migraine

Interventions

Brain Education and WELLness with Migraine Group A

BEHAVIORAL

Brain Education and WELLness with Migraine Group B

BEHAVIORAL

Contacts

Junelyn Floyd

CONTACT

336-713-5776 jgfloyd@wakehealth.edu

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

NCT06641466

Menstrual Migraine

View study

RECRUITINGPHASE3

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713

Chronic Migraine

View study

RECRUITINGNA

Mind Body Balance for Pediatric Migraine

NCT04715685

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 29, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

BE WELL With Migraine: Brain Education and WELLness With Migraine

Inclusion Criteria

Exclusion Criteria

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

Mind Body Balance for Pediatric Migraine

Light Exposure, Migraine Outcomes, and Sleep Quality

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Prophylactic Treatment With Atorvastatin for Episodic Migraine.